Timing of treatment initiation in Parkinson's disease: A need for reappraisal?

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 559-562

  Schapira, Anthony H V ^a   Obeso, Jose ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROTROPHIC FACTOR; RASAGILINE; RILUZOLE; SELEGILINE;

CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

ANTIPARKINSON AGENTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PARKINSON DISEASE; TIME FACTORS;

EID: 33644824423     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20789     Document Type: Short Survey

References (31)

1. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004;55:761-765.
2. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
3. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
4. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
5. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
6. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-2256.
7. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
8. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
9. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
10. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23:S8-S19.
11. Pifl C, Schingnitz G, Hornykiewicz O. Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: the symptromatic versus the asymptomatic condition. Neurochem Int 1992;20(suppl):295S-297S.
12. Sossi V, Fuente-Fernandez R, Holden JE, et al. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24:869-876.
13. Calabresi P, Mercuri NB, Sancesario G, et al. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993;116:433-452.
14. Bezard E, Boraud T, Bioulac B, et al. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur J Neurosci 1999;11:2167-2170.
15. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001;21:6853-6861.
16. Zigmond MJ, Abercrombie ED, Berger TW, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
17. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.
18. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(suppl 3):S26-S36.
19. Schapira AH. Disease modification in Parkinson's disease. Lancet Neurol 2004;3:362-368.
20. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
21. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
22. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
23. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
24. Parkinson Disease Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
25. Parkinson Disease Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
26. Parkinson Disease Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
27. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004;63:S13-S22.
28. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
29. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
30. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-10.
31. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291:358-364.